Fernández-Pastor Begoña, Meana J Javier
Department of Pharmacology, University of the Basque Country, E-48940, Leioa, Bizkaia, Spain.
Eur J Pharmacol. 2002 May 10;442(3):225-9. doi: 10.1016/s0014-2999(02)01543-1.
The regulation of noradrenaline release in the rat cingulate cortex by somatodendritic alpha(2)-adrenoceptors placed in the locus coeruleus was evaluated by dual-probe microdialysis. The alpha(2)-adrenoceptor antagonists BRL44408 (2-[2H-(1-methyl-1,3-dihydroisoindole)methyl]-4,5-dihydroimidazole), RS79948 ((8,12,13)-decahydro-3methoxy-12-(ethylsulphonyl)-6H-isoquino[2,1-g][1,6]-naphthyridine) and RX821002 (2-methoxyidazoxan) administered by reverse dialysis into the locus coeruleus increased concentration-dependently (0.01-100 microM) noradrenaline release in the cortex (maximal effects 170+/-30%, 543+/-17%, 195+/-26%, respectively). Administration of the alpha(2)-adrenoceptor antagonist idazoxan increased at lower (0.1-10 microM) but decreased at the highest dose (100 microM) noradrenaline in the cortex. These data demonstrate that somatodendritic alpha(2)-adrenoceptors in the locus coeruleus exert an inhibitory tonic modulation on noradrenaline release in noradrenergic terminal areas.
通过双探针微透析评估位于蓝斑核的树突体α₂-肾上腺素能受体对大鼠扣带回皮质去甲肾上腺素释放的调节作用。将α₂-肾上腺素能受体拮抗剂BRL44408(2-[2H-(1-甲基-1,3-二氢异吲哚)甲基]-4,5-二氢咪唑)、RS79948((8,12,13)-十氢-3-甲氧基-12-(乙基磺酰基)-6H-异喹啉并[2,1-g][1,6]-萘啶)和RX821002(2-甲氧基咪唑克生)通过反向透析注入蓝斑核后,皮质中的去甲肾上腺素释放呈浓度依赖性增加(0.01 - 100 μM)(最大效应分别为170±30%、543±17%、195±26%)。给予α₂-肾上腺素能受体拮抗剂咪唑克生后,皮质中去甲肾上腺素在较低剂量(0.1 - 10 μM)时增加,但在最高剂量(100 μM)时减少。这些数据表明,蓝斑核中的树突体α₂-肾上腺素能受体对去甲肾上腺素能终末区域的去甲肾上腺素释放发挥抑制性紧张性调节作用。